Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinupramine SCHEMBL29985275 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| Quinupramine SCHEMBL49100 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| Quinupramine SCHEMBL13280380 | 0.82 | SLC6A4 (0.67) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| SCHEMBL13471233 | 0.80 | CHRM2 (0.66) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| SCHEMBL13471238 | 0.80 | ADRA2A (0.66) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| SCHEMBL20216589 | 0.80 | CHRM2 (0.66) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| Amineptine SCHEMBL28280844 | 0.74 | SLC6A3 (0.65) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| SCHEMBL7281251 | 0.71 | CHRM2 (0.55) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| SCHEMBL7290543 | 0.71 | CHRM2 (0.55) | CHRM2CHRM1HTR1AADRA2ADRD1 | |
| SCHEMBL24903369 | 0.68 | SLC18A3 (0.53) | CHRM2CHRM1HTR1AADRA2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117597126-A | Pharmaceutical composition for preventing or treating cancer comprising CDK4/6 inhibitor and tricyclic antidepressant | 国立癌症中心 | 2024-02-23 | — | — | CN | claimed |
| WO-2023282544-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | 국립암센터 | 2023-01-12 | — | — | WO | claimed |
| EP-2729136-A1 | DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION | Biocopea Limited (GB) | 2014-05-14 | — | — | EP | claimed |
| WO-2013004999-A1 | DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION | BIOCOPEA LIMITED (GB) | 2013-01-10 | — | — | WO | claimed |
| CN-102595894-A | Compounds that treat malaria and prevent malaria transmission | USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES | 2012-07-18 | — | — | CN | claimed |
| CN-101132777-A | Pharmaceutical compositions for sleep disorders | COLLEGIUM PHARMACEUTICAL INC (US) | 2008-02-27 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | disclosed |
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2026-01-20 | — | — | US | disclosed |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2024-10-24 | — | — | US | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| EP-0710106-A1 | METHOD OF TREATING ADDICTIVE BEHAVIORS | HITZIG, Pietr (US) | 1996-05-08 | — | — | EP | disclosed |
| US-5502080-A | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders | HITZIG PIETR (US) | 1996-03-26 | — | — | US | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1994021244-A1 | METHOD OF TREATING ADDICTIVE BEHAVIORS | HITZIG PIETR (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564596-B2 | Agents and methods for modulating pathogen activity | C3AR1, HTR3A, CHRM3 | CHRM2 18/4885CHRM1 12/4885HTR1A 26/4885 |
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | CHRM2 1532/4885CHRM1 2063/4885HTR1A 20/4885 |
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2C, GRIN3A, GRIN1 | CHRM2 805/4885CHRM1 404/4885HTR1A 45/4885 |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | CHRM2 1532/4885CHRM1 2063/4885HTR1A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.